The In Vitro Fertilization (IVF) market is currently experiencing explosive growth. Procedural volumes are surging, and “embryo banking”—the strategic cryopreservation of multiple embryos—has become a standard practice. Technology has grown more sophisticated, treatment options have diversified, and accessibility has improved. On the surface, IVF is clearly in an era of “progress.”
Yet, the data raises a troubling question: are we actually achieving better results?
Recent trends show that the number of IVF cycle starts has increased by approximately 234%. Simultaneously, the utilization of embryo freezing has skyrocketed by nearly 900%. This is the friction point: during the same period, the success rate per cycle has actually declined from 29% to 22%. We have seen a quantitative explosion, yet a qualitative dilution in efficiency.
This paradox is not merely a statistical anomaly. It is a sign that the fundamental structure of IVF is being rewritten.
The Shift in Strategy: From “One-Shot” to Cumulative Success The first major shift is strategic: moving from “single-cycle success” to “multi-cycle planning.” In the past, the core objective was to achieve pregnancy within a single fresh embryo transfer cycle. Today, the prevailing strategy is to create multiple embryos, freeze them, and utilize them over time according to clinical circumstances. Consequently, the “success rate per cycle” is an inherently flawed metric because a single cycle no longer dictates the final outcome.
The PGT-A Controversy The widespread adoption of PGT-A (Preimplantation Genetic Testing for Aneuploidy) is a second major driver. Theoretically, the strategy of selecting only euploid (genetically normal) embryos is compelling. It aims to reduce failure and increase pregnancy rates, and for specific patient subsets, it does offer meaningful benefits. However, when viewed at a population level, the narrative becomes more complex. The selection process often leaves fewer “transferable” embryos, reducing the number of cycles that progress to transfer. We are creating a larger denominator of starting cycles, while the numerator—live births—fails to keep pace. Furthermore, debates regarding “mosaic embryo” interpretation and diagnostic accuracy have left PGT-A caught in a crossfire: is it a tool for efficiency, or a strategy that merely extends the clinical process?
The Changing Patient Profile Third, the patient demographic has changed. IVF is no longer the “last resort.” A broader spectrum of ages and clinical conditions are entering the IVF pathway. In particular, the increasing proportion of older patients naturally exerts downward pressure on overall success rates. Therefore, this decline in success rates does not necessarily signal a “technological regression.”
Defining “Success” Nevertheless, the data conveys an undeniable message: IVF has entered an era of quantitative expansion. We are performing more procedures, creating more embryos, and navigating more choices—but the efficiency of the individual cycle is becoming increasingly diluted.
At this intersection, a critical question remains: How do we define “success”?
Is it the success rate per cycle, the cumulative pregnancy rate, or the ultimate live birth rate? Depending on which indicator you choose, IVF reveals an entirely different face. The current decline may not represent failure, but rather a transition to a new set of metrics. Alternatively, it may signal that technology is drifting toward “clinical over-intervention.”
We are in the midst of a paradigm shift. Understanding whether this shift represents true advancement or a dilution of efficiency will be the defining challenge for reproductive medicine in the coming years.
Sources: ASRM National ART Statistics Report (2022–2024); CDC National Summary Report; ESHRE European ART Data Report (2018–2022); Human Reproduction; Fertility and Sterility; Reproductive BioMedicine Online.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and various public data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.